| Literature DB >> 35992984 |
N Singh1, V Trivedi1, V Kumar1, N K Mishra1, S Ahmad2, S J Ayar1, S S Kataria1, H Kharbanda1.
Abstract
Introduction: Osteoarthritis (OA) is estimated to be the fourth leading cause of disability in the general population. It probably is the most common disease of joints in adults throughout the world. Knee OA accounts for more than 80% of the disease's total burden and as per an estimate in US population, it affects at least 19% of adults aged 45 years and older. This was a randomised study aimed to evaluate the efficacy of platelet rich plasma (PRP) as a treatment modality for osteoarthritis knee in comparison to arthroscopic management. Materials and methods: This study was conducted from 2018 to 2020 at a tertiary care teaching hospital, under reference number ELMC&H/RCELL2019/39. A total of 70 patients of osteoarthritis knee with grade 2-3 according to the Kellgren-Lawrence classification were selected using computer generated random number among them 35 patients were subjected to arthroscopy (Group II) and 35 were administered platelet rich plasma injection (Group I) and evaluated at 3, 6 and 9 months of follow-up. Both the groups were assessed and scored with the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Visual Analog Pain Scale (VAS) to compare pre-treatment and post-treatment values. As all the patients in the sample was followed-up, resulting into no loss of subjects. Result: Overall, percentage reduction in VAS score at 3 months, 6 months, and 9 months was 24.45±9.09, 18.45±11.60 and 8.29±14.19%, respectively in Group I and 18.96±5.85, 7.33±8.60 and 3.20±7.39%, respectively in Group II. A statistically significant difference between two groups was observed at 3- and 6-months' time intervals only (p<0.05). Overall, percentage reduction in WOMAC score at 3 months, 6 months and 9 months was 24.03±11.41, 17.45±9.24, and 9.49±9.80%, respectively in Group I and 11.27±5.73, 5.70±4.78, and -0.13±5.06%, respectively in Group II. At all the three-time intervals, the difference between two groups was significant statistically (p<0.001).Entities:
Keywords: Kellgren-Lawrence; PRP; WOMAC; arthroscopy; osteoarthritis
Year: 2022 PMID: 35992984 PMCID: PMC9388795 DOI: 10.5704/MOJ.2207.004
Source DB: PubMed Journal: Malays Orthop J ISSN: 1985-2533
Fig 1:Flow chart of randomised control study
Comparison of General Profile and Disease Characteristics of patients in two groups
| Group I (n=35) | Group I (n=35) | Statistical significance | ||||
|---|---|---|---|---|---|---|
| 1. | Mean age±SD (Range) | 53.23±7.81 (40-60) | 54.80±5.74 (44-60) | ‘t’ = 0.960; p = 0.341 | ||
| No. | % | No. | % | |||
| 2. | Gender | |||||
| Male | 11 | 31.4 | 13 | 37.1 | χ2 = 0.254; p = 0.615 | |
| Female | 24 | 68.6 | 22 | 62.9 | ||
| 3. | Habitat | |||||
| Rural | 5 | 14.3 | 12 | 34.3 | χ2 = 3.807; p = 0.051 | |
| Urban | 30 | 85.7 | 23 | 65.7 | ||
| 4. | Occupation | |||||
| Business | 8 | 22.9 | 8 | 22.9 | χ2 = 3.287; p = 0.349 | |
| Farmer | 3 | 8.6 | 2 | 5.7 | ||
| Housewife | 24 | 68.6 | 22 | 62.9 | ||
| Shopkeeper | 0 | 0.0 | 3 | 8.6 | ||
| 5. | Side | |||||
| Bilateral | 28 | 80.0 | 24 | 68.6 | χ2 = 1.641; p = 0.440 | |
| Left only | 3 | 8.6 | 3 | 8.6 | ||
| Right only | 4 | 11.4 | 8 | 22.9 | ||
| 6. | Varus deformity | 14 | 40.0 | 18 | 51.4 | χ2 = 0.921; p = 0.337 |
| 7. | Limitation of extension | 11 | 31.4 | 17 | 48.6 | χ2 = 2.143; p = 0.143 |
| 8. | Swelling | 21 | 60.0 | 18 | 51.4 | χ2 = 0.521; p = 0.470 |
| 9. | Mean duration of symptoms±SD (Range) in months | 6.66±4.35 (1-18) | 6.86±4.88 (1-24) | ‘t’ = 0.182; p = 0.857 | ||
| 10. | Mean BMI±SD (Range) in kg/m2 | 28.88±2.50 (22.50-33.20) | 28.09±3.03 (23.50-35.10) | ‘t’ = 1.197; p = 0.236 | ||
| 11. | Mean Pre-op. WOMAC±SD (Range) | 55.97±6.24 (45-72) | 58.17±6.89 (45-72) | ‘t’ = 9.203; p = 0.166 | ||
| 12. | Mean Pre-op. VAS±SD (Range) | 6.06±0.73 (5-8) | 6.43±0.85 (5-8) | ‘t’ = 1.966; p = 0.053 | ||
| 13. | Nutr. Status (Asian Criteria) | No. | % | No. | % | |
| Normal (18.5-22.9) | 1 | 2.9 | 0 | 0.0 | χ2 = 3.155; p = 0.368 | |
| Overweight (23-24.9) | 2 | 5.7 | 6 | 17.1 | ||
| Pre-obese (25-29.9) | 18 | 51.4 | 16 | 45.7 | ||
| Obese type I (30-40.0) | 14 | 40.0 | 13 | 37.1 | ||
Comparison of two groups according to Pre-intervention KL Grade
| SN | Grade | Group I (n=35) | Group II (n=35) | ||
|---|---|---|---|---|---|
| No. % | No. % | No. % | No. % | ||
| 1. | KL Grade 2 | 19 | 54.3 | 14 | 40.0 |
| 2. | KL Grade 3 | 16 | 45.7 | 21 | 60.0 |
χ2 = 1.433; p = 0.231
Comparison of two groups according to Pre-intervention WOMAC scores
| SN | Variable | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | KL Grade 2 | 19 | 52.32 | 4.03 | 14 | 54.36 | 7.69 | -0.991 | 0.330 |
| 2. | KL Grade 3 | 16 | 60.31 | 5.64 | 21 | 60.71 | 5.02 | -0.229 | 0.820 |
| 3. | Overall | 35 | 55.97 | 6.24 | 35 | 58.17 | 6.89 | -1.400 | 0.166 |
Comparison of two groups according to Pre-intervention VAS scores
| SN | Variable | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | KL Grade 2 | 19 | 5.63 | 0.60 | 14 | 6.00 | 1.11 | -1.230 | 0.228 |
| 2. | KL Grade 3 | 16 | 6.56 | 0.51 | 21 | 6.71 | 0.46 | -0.944 | 0.352 |
| 3. | Overall | 35 | 6.06 | 0.73 | 35 | 6.43 | 0.85 | -1.966 | 0.053 |
Comparison of post-intervention WOMAC scores at different follow-up intervals
| SN | Follow-up interval | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | At 3 months | ||||||||
| KL Grade 2 | 19 | 35.63 | 2.71 | 14 | 47.43 | 7.52 | -6.330 | <0.001 | |
| KL Grade 3 | 16 | 51.19 | 6.91 | 21 | 54.43 | 4.93 | -1.667 | 0.104 | |
| Overall | 35 | 42.74 | 9.32 | 35 | 51.63 | 6.93 | 4.528 | <0.001 | |
| 2. | At 6 months | ||||||||
| KL Grade 2 | 19 | 40.11 | 2.77 | 14 | 50.93 | 7.28 | -5.950 | <0.001 | |
| KL Grade 3 | 16 | 53.75 | 6.16 | 21 | 57.43 | 4.99 | -2.009 | 0.052 | |
| Overall | 35 | 46.34 | 9.32 | 35 | 54.83 | 6.73 | 4.709 | <0.001 | |
| 3. | At 9 months | ||||||||
| KL Grade 2 | 19 | 44.32 | 4.22 | 14 | 53.64 | 7.33 | -4.618 | <0.001 | |
| KL Grade 3 | 16 | 58.56 | 6.87 | 21 | 61.19 | 4.40 | -1.416 | 0.166 | |
| Overall | 35 | 50.83 | 9.06 | 35 | 58.17 | 6.78 | 3.838 | <0.001 | |
Comparison of post-intervention VAS scores at different follow-up intervals
| SN | Follow-up interval | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | At 3 months | ||||||||
| KL Grade 2 | 19 | 4.00 | 0.58 | 14 | 4.71 | 0.73 | -3.149 | 0.004 | |
| KL Grade 3 | 16 | 5.31 | 0.70 | 21 | 5.52 | 0.51 | -1.058 | 0.297 | |
| Overall | 35 | 4.60 | 0.91 | 35 | 5.20 | 0.72 | -3.052 | 0.003 | |
| 2. | At 6 months | ||||||||
| KL Grade 2 | 19 | 4.53 | 0.61 | 14 | 5.43 | 0.65 | -4.089 | <0.001 | |
| KL Grade 3 | 16 | 5.44 | 1.09 | 21 | 6.24 | 0.44 | -3.061 | 0.004 | |
| Overall | 35 | 4.94 | 0.97 | 35 | 5.91 | 0.66 | -4.907 | <0.001 | |
| 3. | At 9 months | ||||||||
| KL Grade 2 | 19 | 5.21 | 0.63 | 14 | 5.64 | 0.74 | -1.803 | 0.081 | |
| KL Grade 3 | 16 | 5.94 | 1.34 | 21 | 6.57 | 0.60 | -1.936 | 0.061 | |
| Overall | 35 | 5.54 | 1.07 | 35 | 6.20 | 0.80 | -2.920 | 0.005 | |
Comparison of percent reduction in WOMAC scores between two groups at different follow-up intervals
| SN | Follow-up interval | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | 3 months | ||||||||
| KL Grade 2 | 19 | 31.59 | 6.61 | 14 | 12.78 | 5.56 | 8.621 | <0.001 | |
| KL Grade 3 | 16 | 15.05 | 9.17 | 21 | 10.26 | 5.75 | 1.944 | 0.060 | |
| Overall | 35 | 24.03 | 11.41 | 35 | 11.27 | 5.73 | 5.911 | <0.001 | |
| 2. | 6 months | ||||||||
| KL Grade 2 | 19 | 23.11 | 5.60 | 14 | 6.24 | 4.80 | 9.069 | <0.001 | |
| KL Grade 3 | 16 | 10.72 | 8.19 | 21 | 5.34 | 4.85 | 2.495 | 0.017 | |
| Overall | 35 | 17.45 | 9.24 | 35 | 5.70 | 4.78 | 6.678 | <0.001 | |
| 3. | 9 months | ||||||||
| KL Grade 2 | 19 | 15.20 | 5.62 | 14 | 1.14 | 5.14 | 7.366 | <0.001 | |
| KL Grade 3 | 16 | 2.71 | 9.45 | 21 | -0.97 | 4.95 | 1.534 | 0.134 | |
| Overall | 35 | 9.49 | 9.80 | 35 | -0.13 | 5.06 | 5.161 | <0.001 | |
Comparison of overall percent reduction in VAS Score between two groups at nine months (final follow-up)
| SN | Variable | Group I | Group II | Statistical significance | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | SD | ‘t’ | ‘p’ | ||
| 1. | 3 months | ||||||||
| KL Grade 2 | 19 | 28.87 | 8.24 | 14 | 20.86 | 6.02 | 3.078 | 0.004 | |
| KL Grade 3 | 16 | 19.20 | 7.19 | 21 | 17.69 | 5.51 | 0.723 | 0.474 | |
| Overall | 35 | 24.45 | 9.09 | 35 | 18.96 | 5.85 | 3.006 | 0.004 | |
| 2. | 6 months | ||||||||
| KL Grade 2 | 19 | 19.70 | 5.14 | 14 | 8.12 | 10.50 | 4.189 | <0.001 | |
| KL Grade 3 | 16 | 16.96 | 16.40 | 21 | 6.80 | 7.31 | 2.536 | 0.016 | |
| Overall | 35 | 18.45 | 11.60 | 35 | 7.33 | 8.60 | 4.554 | <0.001 | |
| 3. | 9 months | ||||||||
| KL Grade 2 | 19 | 7.24 | 8.81 | 14 | 4.76 | 9.65 | 0.768 | 0.448 | |
| KL Grade 3 | 16 | 9.52 | 18.99 | 21 | 2.15 | 5.42 | 1.697 | 0.099 | |
| Overall | 35 | 8.29 | 14.19 | 35 | 3.20 | 7.39 | 1.881 | 0.064 | |